EX-99.1 2 exhibit991q22019earningsre.htm EXHIBIT 99.1 Exhibit
Exhibit 99.1
cstllogoa01.jpg

Castle Biosciences Reports Second Quarter 2019 Results

•
Q2 2019 DecisionDx-Melanoma test report volume increased 27% compared to Q2 2018
•
Q2 2019 recognized revenues increased to $10.7 million, up from $4.0 million in Q2 2018
•
Q2 2019 gross margin increased to 81%, up from 67% in Q2 2018
 
FRIENDSWOOD, Texas--(BUSINESS WIRE)--September 3, 2019--Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the second quarter and six months ended June 30, 2019.

“We are pleased with our strong second quarter performance, including our 27% year-over-year growth in DecisionDx-Melanoma test report volume, which we believe was largely driven by our successful first quarter 2019 commercial expansion,” said Derek Maetzold, President and CEO of Castle Biosciences. “We are also encouraged by the success of our recently completed initial public offering and the strong level of interest from our investors. We believe the proceeds from our initial public offering, combined with our existing working capital, position us to execute upon our expansion plans and fund research and development activities.”

Second Quarter Ended June 30, 2019 Financial Highlights

•
Revenues of $10.7 million, an increase of $6.8 million from Q2 2018.
•
Delivered 4,067 DecisionDx®-Melanoma and DecisionDx®-UM proprietary test reports, an increase of 24% over Q2 2018, with DecisionDx-Melanoma having an increase of 27%.
•
Gross margin of $8.7 million, or 81%, compared to $2.7 million, or 67% for Q2 2018.

Six Months Ended June 30, 2019 Financial Highlights

•
Revenues of $19.5 million, an increase of $11.8 million from the first half of 2018.
•
Delivered 7,659 DecisionDx-Melanoma and DecisionDx-UM proprietary test reports, an increase of 21% over the same period in 2018, with DecisionDx-Melanoma having an increase of 23%.
•
Gross margin of $15.9 million, or 82%, compared to $5.1 million, or 66% for the first half of 2018.

Supplemental Revenue Information

Affecting the year-over-year comparability of our revenues were (a) the issuance of the Medicare Local Coverage Determination (LCD) for our DecisionDx-Melanoma test, effective December 3, 2018 and (b) confirmation of the Medicare Contractor rate for DecisionDx-Melanoma. As a result of timing of these two elements, all 2018 Medicare claims covered under the LCD were recognized as revenue in the fourth quarter of 2018. Medicare revenues for DecisionDx-Melanoma associated with test reports delivered in the three and six months ended June 30, 2018, but not recorded until the fourth quarter of 2018, were $2.2 million and $3.0 million, respectively. Also, included in revenues for the quarter ended June 30, 2019 and 2018 were positive (negative) revenue adjustments related to tests delivered in prior periods of $3.3


million and $(0.8) million, respectively. For the six months ended June 30, 2019 and 2018, these amounts totaled $2.8 million and $0.9 million, respectively.

Second Quarter Business and Clinical Evidence Updates

•
An independent, prospective study from investigators at the Saint Louis University Hospital was published during the second quarter in the journal Cancer Medicine. The study demonstrated that DecisionDx-Melanoma accurately identified risk of melanoma recurrence independent of other prognostic factors such as Breslow thickness and sentinel lymph node biopsy. The results are consistent with previously published prospective and retrospective studies demonstrating the high performance of DecisionDx-Melanoma to predict outcomes, supporting its clinical value to inform patient management decisions.
•
American Skin Association (ASA) honored Castle Biosciences with the 2019 Technology Innovation in Melanoma Award for advancing innovative technology in the field of dermatology.
•
Poster at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting presented updated results from a prospective, multicenter study demonstrating the accuracy and performance of DecisionDx-Melanoma with median follow-up of over 3 years. Three-year overall survival for patients with T1-T2 melanoma and a DecisionDx-Melanoma Class 1A test result was greater than 99%, providing support for the use of a DecisionDx-Melanoma Class 1A test result to identify patients at low risk for a positive sentinel lymph node biopsy result, allowing patients to avoid the invasive surgical procedure.
•
Poster at the 2019 Fall Clinical Dermatology Conference for PAs & NPs highlighted accuracy of DecisionDx-Melanoma risk prediction in newly expanded cumulative patient cohort of 901 patients.
•
Presentation at the 2019 American College of Mohs Surgery (ACMS) Annual Meeting highlighted progress in the development of Castle Biosciences’ gene expression profile (GEP) test candidate for use in cutaneous squamous cell carcinoma (cSCC).

Financing, Liquidity and IPO

As of June 30, 2019, our cash balance was $17.5 million and the outstanding principal balance on our bank term loan was $26.7 million. Subsequently, on July 12, 2019, we issued a $10.0 million convertible promissory note and on July 29, 2019, we completed our IPO, which resulted in net proceeds of approximately $66.0 million, after deducting underwriting discounts and commissions and other offering expenses.

Recent Developments

On August 22, 2019, Palmetto GBA, a Medicare Administrative Contractor, posted a draft LCD that, if finalized, would result in expanded Medicare coverage for our DecisionDx-Melanoma test. We expect that Palmetto GBA will finalize and implement the draft LCD after a public comment period that opens on October 7, 2019 and closes on November 21, 2019.

The nineteenth peer-reviewed publication supporting DecisionDx-Melanoma use was published in the journal Skin in early July. This study was an evidence-based analysis of the clinical performance and utility of DecisionDx-Melanoma using four different datasets ranging in size from 403 to 8,944 patients. The study focused on identifying a tumor thickness that would be appropriate for use of the test to guide follow-up decisions for cutaneous melanoma patients. Results demonstrate that a tumor thickness of 0.3 mm and thicker is an appropriate population in which to use DecisionDx-Melanoma to guide follow-up

2

decisions. Note that previously published validation, performance and utility studies support the two primary clinical uses of the DecisionDx-Melanoma test following the diagnosis of melanoma. The first use is to inform decisions on sentinel lymph node biopsy in most eligible patients with tumor thickness less than or equal to 2.0 mm with no minimum tumor thickness, and the second is to guide follow-up decisions.

Conference Call Details

Castle Biosciences will hold a conference call on September 3, 2019 at 4:30 p.m. Eastern time to discuss its second quarter 2019 results and provide a general business update.

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/tk8ypudk. Please access the webcast at least 10 minutes before the conference call start time.

To access the live conference call via phone, please dial 877-282-2581 from the United States and Canada, or +1 470-495-9479 internationally, at least 10 minutes prior to the start of the call, using the conference ID 2368125.
A replay of the webcast will be available for two weeks following the conclusion of the live broadcast and will be accessible on the Investors section of the company’s website at www.CastleBiosciences.com.
About Castle Biosciences, Inc.

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq; www.SkinMelanoma.com) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®- UMSeq; www.MyUvealMelanoma.com), with products in development for other underserved cancers, the two most advanced of which are focused on patients with cutaneous squamous cell carcinoma, and patients who have a difficult-to-diagnose pigmented lesion. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit www.CastleBiosciences.com.

Forward-Looking Statements
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our positioning to execute our strategic plans and fund research and development activities, the outcome of the draft LCD issued by Palmetto GBA and its process for finalizing the draft LCD, our prospects and plans and the objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements

3

that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in our final prospectus filed with the SEC on July 26, 2019 relating to our Registration Statements on Form S-1 (File Nos. 333-232369 and 333-232796) and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.

Investor Contact:
Frank Stokes
Chief Financial Officer
866-788-9007
ir@castlebiosciences.com

4


CASTLE BIOSCIENCES, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
NET REVENUES
$
10,738,569

 
$
3,979,381

 
$
19,455,556

 
$
7,637,946

COST OF SALES
1,992,784

 
1,326,839

 
3,590,742

 
2,579,822

Gross margin
8,745,785

 
2,652,542

 
15,864,814

 
5,058,124

OPERATING EXPENSES
 
 
 
 
 
 
 
Research and development
1,317,237

 
1,159,197

 
2,711,088

 
2,421,887

Selling, general and administrative
6,820,927

 
4,159,755

 
12,867,549

 
8,387,546

Total operating expenses
8,138,164

 
5,318,952

 
15,578,637

 
10,809,433

Operating income (loss)
607,621

 
(2,666,410
)
 
286,177

 
(5,751,309
)
Interest income
5,529

 
2,240

 
26,318

 
7,623

Interest expense
(1,692,582
)
 
(524,843
)
 
(2,716,982
)
 
(1,055,068
)
Other income (expense), net
(189,647
)
 
34,038

 
(222,575
)
 
13,340

Loss before income taxes
(1,269,079
)
 
(3,154,975
)
 
(2,627,062
)
 
(6,785,414
)
Income tax expense
—

 
—

 
—

 
—

Net loss and comprehensive loss
(1,269,079
)
 
(3,154,975
)
 
(2,627,062
)
 
(6,785,414
)
Convertible preferred stock cumulative dividends
938,892

 
869,008

 
1,867,467

 
1,678,330

Accretion of redeemable convertible preferred stock to redemption value
56,775

 
55,795

 
112,573

 
105,020

Net loss and comprehensive loss attributable to common stockholders
$
(2,264,746
)
 
$
(4,079,778
)
 
$
(4,607,102
)
 
$
(8,568,764
)
 
 
 
 
 
 
 
 
Loss per share attributable to common stockholders, basic and diluted
$
(1.05
)
 
$
(2.15
)
 
$
(2.26
)
 
$
(4.52
)
 
 
 
 
 
 
 
 
Weighted-average shares outstanding, basic and diluted
2,152,965

 
1,897,084

 
2,035,393

 
1,897,070



5

CASTLE BIOSCIENCES, INC.
CONDENSED BALANCE SHEET
 
June 30, 2019
 
December 31, 2018
 
(unaudited)
 
 
ASSETS
 

 
 

Current Assets
 

 
 

Cash and cash equivalents
$
17,468,466

 
$
4,478,512

Accounts receivable, net
9,730,319

 
12,089,719

Inventory
550,894

 
882,233

Prepaid expenses and other current assets
774,885

 
675,562

Total current assets
28,524,564

 
18,126,026

 
 
 
 
Long-term accounts receivable, net
1,266,098

 
2,532,011

Property and equipment, net
1,743,170

 
1,528,996

Intangible assets, net
—

 
4,167

Other assets – long-term
1,813,311

 
213,735

Total assets
$
33,347,143

 
$
22,404,935

 
 
 
 
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
 
 
 
Current Liabilities
 
 
 
Accounts payable
$
2,084,910

 
$
1,450,766

Accrued compensation
2,784,746

 
4,571,011

Other accrued liabilities
1,616,866

 
715,244

Current portion of long-term debt
833,333

 
—

Convertible promissory notes
4,425,819

 
—

Total current liabilities
11,745,674

 
6,737,021

Long-term debt
23,858,781

 
24,499,752

Preferred stock warrant liability
1,279,840

 
1,193,726

Deferred rent liability
56,690

 
43,587

Total liabilities
36,940,985

 
32,474,086

Convertible Preferred Stock
 
 
 
Convertible preferred stock Series C
1,500,994

 
1,500,994

Redeemable convertible preferred stock Series A, B, D, E-1, E-2, E-2A, E-3 and F
45,107,730

 
44,995,157

 
 
 
 
Stockholders’ Deficit
 
 
 
Common stock
2,192

 
1,916

Additional paid-in capital
9,910,882

 
921,360

Accumulated deficit
(60,115,640
)
 
(57,488,578
)
Total stockholders’ deficit
(50,202,566
)
 
(56,565,302
)
Total liabilities, convertible preferred stock and stockholders’ deficit
$
33,347,143

 
$
22,404,935





6

CASTLE BIOSCIENCES, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
 
Six Months Ended June 30,
 
2019
 
2018
OPERATING ACTIVITIES
 

 
 
Net loss
$
(2,627,062
)
 
$
(6,785,414
)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
 
 
 
Depreciation
163,285

 
141,495

Stock compensation expense
307,229

 
146,340

Amortization of intangibles
4,167

 
18,673

Amortization of debt discounts and issuance costs
1,249,964

 
286,798

Change in fair value of preferred stock warrant liability
86,114

 
(13,341
)
Change in fair value of embedded derivative
136,461

 
—

Other
337

 
—

Change in operating assets and liabilities:
 
 
 
Accounts receivable
3,625,313

 
(621,175
)
Prepaid expenses and other current assets
(99,323
)
 
38,209

Inventory
331,339

 
(101,676
)
Other assets
(12,057
)
 
(100,968
)
Accounts payable
(524,029
)
 
(607,683
)
Accrued compensation
(1,786,265
)
 
331,465

Other accrued liabilities
901,622

 
33,305

Deferred rent liability
13,103

 
28,249

Net cash provided by (used in) operating activities
1,770,198

 
(7,205,723
)
 
 
 
 
INVESTING ACTIVITES
 
 
 
Purchases of property and equipment
(424,473
)
 
(184,610
)
Net cash used in investing activities
(424,473
)
 
(184,610
)
 
 
 
 
FINANCING ACTIVITIES
 
 
 
Proceeds from issuance of preferred stock and preferred stock warrants (including exercised warrants)
—

 
10,382,507

Proceeds from issuance from convertible promissory notes, net of issuance costs
11,695,495

 
—

Proceeds from issuance of term debt, net of issuance costs
1,776,145

 
—

Proceeds from line of credit
—

 
1,000,000

Repayments on line of credit
(1,791,145
)
 
—

Payment of deferred offering costs
(453,816
)
 
—

Proceeds from exercise of common stock options
417,550

 
1,065

Net cash provided by financing activities
11,644,229

 
11,383,572

 
 
 
 
NET CHANGE IN CASH AND CASH EQUIVALENTS
12,989,954

 
3,993,239

Beginning of period
4,478,512

 
1,212,063

End of period
$
17,468,466

 
$
5,205,302


7